<DOC>
	<DOC>NCT01125527</DOC>
	<brief_summary>This study will evaluate the safety and immunogenicity of single dose of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 13-59 months of age.</brief_summary>
	<brief_title>Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Infants 1359 months of age. Prior Hib vaccine administration. History of serious reaction(s) following vaccination. Any vaccination within 7 days of study vaccination. Known or suspected immune impairment. Premature (before 37th week of gestation) or birth weight less than 2500g For additional entry criteria please refer to the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>13 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Haemophilus influenzae type b (Hib)</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Anti PRP antibody</keyword>
</DOC>